Study shows Moderna vaccine maintains antibodies against Variants of Concern and Interest

Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose

Moderna to set up mRNA manufacturing in Canada

The collaboration will support Canada with direct access to rapid pandemic response capabilities

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab

Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna

Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio

Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine

New agreement for three further production lines at Lonza’s site in Visp, Switzerland

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.

New diabetes drug UBT251 shows strong phase 2 results in China

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency